Attorneys general for 35 states filed suit Thursday against the makers of the Suboxone, a drug used to treat opioid addiction, alleging they schemed to stall the entry of a generic form of the drug into the market.
The states accuse Reckitt Benckiser Pharmaceuticals and Indivior of conspiring with MonoSol Rx to switch Suboxone from a tablet to a dissolving film before the drug’s exclusivity period barring generic competition was up, according to the complaint filed in U.S. District Court for the Eastern District of Pennsylvania. This delay tactic ran afoul of state and federal antitrust laws, the states’ attorneys said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
